- Home
- SLDB vs AMLX Comparison
SLDB vs AMLX Comparison
Compare SLDB & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDB
- AMLX
- Stock Information
- Founded
- SLDB 2013
- AMLX 2014
- Country
- SLDB United States
- AMLX United States
- Employees
- SLDB N/A
- AMLX N/A
- Industry
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- SLDB Health Care
- AMLX Health Care
- Exchange
- SLDB Nasdaq
- AMLX Nasdaq
- Market Cap
- SLDB 366.2M
- AMLX 330.5M
- IPO Year
- SLDB 2018
- AMLX 2022
- Fundamental
- Price
- SLDB $3.65
- AMLX $5.15
- Analyst Decision
- SLDB Strong Buy
- AMLX Buy
- Analyst Count
- SLDB 9
- AMLX 4
- Target Price
- SLDB $15.67
- AMLX $8.50
- AVG Volume (30 Days)
- SLDB 1.3M
- AMLX 815.5K
- Earning Date
- SLDB 05-14-2025
- AMLX 05-08-2025
- Dividend Yield
- SLDB N/A
- AMLX N/A
- EPS Growth
- SLDB N/A
- AMLX N/A
- EPS
- SLDB N/A
- AMLX N/A
- Revenue
- SLDB N/A
- AMLX $87,371,000.00
- Revenue This Year
- SLDB N/A
- AMLX N/A
- Revenue Next Year
- SLDB $569.02
- AMLX N/A
- P/E Ratio
- SLDB N/A
- AMLX N/A
- Revenue Growth
- SLDB N/A
- AMLX N/A
- 52 Week Low
- SLDB $2.45
- AMLX $1.58
- 52 Week High
- SLDB $10.99
- AMLX $7.27
- Technical
- Relative Strength Index (RSI)
- SLDB 49.73
- AMLX 76.32
- Support Level
- SLDB $2.48
- AMLX $3.79
- Resistance Level
- SLDB $2.88
- AMLX $4.05
- Average True Range (ATR)
- SLDB 0.31
- AMLX 0.34
- MACD
- SLDB 0.10
- AMLX 0.16
- Stochastic Oscillator
- SLDB 86.97
- AMLX 99.03
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.